Risk factors of chronic hepatitis in antiretroviral-treated HIV infection, without hepatitis B or C viral infection

Table 4 Antiretroviral use* of HIV patients with or without chronic non HBV/HCV hepatitis**

Clinical parameters	Case	Control	p value
	(n = 124)	(n = 124)
Median, duration of ARV exposure (years) (IQR)	2.2(0.9-5.2)	1.6(0.9-4.4)	0.18
Antiretroviral regimens (n, %)
o Triple NRTIs	18(14.5)	-	NA
o Dual NRTIs plus NNRTI	46(37.1)	52(41.9)	0.37
o Dual NRTIs plus boosted PIs	58(46.8)	65(54.4)	0.29
o NNRTIs plus boosted PIs	2(1.6)	7(5.7)	0.12

Abbreviation: NRTIs Nucleoside reverse transcriptase inhibitors, NNRTI Non-nucleoside reverse transcriptase inhibitor, PIs Protease inhibitors, ARV Antiretroviral, IQR Interquartile range, NA Non applicable.
* Ever exposed to antiretroviral medication.
**Chronic hepatitis was defined as those with elevated ALT ≥ 40 IU/L at 2 consecutive visits 6 months apart.

ISSN: 1742-6405